Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks
Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks - a Single-center Study
Loyola University
40 participants
Jan 1, 2023
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to learn about how the use of 500 mg of dried cranberry powder extract (NDS-446) changes the bacteria that normal reside in the bladder of women who don't have urinary leakage problems but do have problems with urinary urgency and frequency.
Eligibility
Inclusion Criteria3
- years, female, ambulatory
- OAB symptoms > 6 months
- Voiding frequency > 8 times in 24 hrs and > 3 episodes of urgency (grade 3 or 4) without incontinence during 3-day diary at baseline
Exclusion Criteria12
- Self-reported urinary incontinence (> 3 episodes in the month prior)
- UTI > 3 in last 12 months
- A diagnosis of painful bladder syndrome or interstitial cystitis
- LUT surgery last 6 months
- Drug or non-drug treatment of OAB (previous 60 days) or current meds that affect detrusor activity
- On Warfarin
- Failure to complete 3-day diary
- Aspirin > 81 mg daily
- Gross hematuria
- Allergy or sensitivity to aspirin
- Subjects taking anti-platelet agents
- Inability to swallow capsules
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
All participants will receive 500 mg NDS-446 daily for 12 weeks following a baseline assessment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05557279